AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials

In COVID-19, Critical Care, Emergency Medicine, Family Practice, HealthDay News, Internal Medicine, Latest News, OBGYN & Women's Health, Pharmacy
by Healthday

U.S. Food and Drug Administration authorized the restart after reviewing all safety data

MONDAY, Oct. 26, 2020 (HealthDay News) — Drugmakers AstraZeneca and Johnson & Johnson are ready to resume paused COVID-19 vaccine trials after health scares, CNN reported.

The AstraZeneca trial was stopped in early September, and the Johnson & Johnson trial was paused earlier this month.

The U.S. Food and Drug Administration authorized the restart after reviewing all the safety data, CNN reported. The AstraZeneca trial has already resumed in other countries. That trial was stopped after a volunteer in Britain developed an unexplained neurological condition. The Johnson & Johnson trial was halted because one participant had an “unexplained illness,” for which “no clear cause” was identified, the company said.

Government health officials and outside experts have said the holds are an example of how the safety process is protecting Americans from any potentially dangerous vaccines, CNN reported.

CNN Article

Copyright © 2020 HealthDay. All rights reserved.